Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gefitinib in EGFR-positive advanced non-squamous NSCLC (real-world study)
ChiCTR2000040093Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
Rivoceranibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000040093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040093.